



Press release

Stockholm, June 7, 2006

## Clinical Data on Molecular Imaging of Breast Cancer Metastases using anti-HER2 Affibody<sup>®</sup> molecules

**STOCKHOLM, Sweden, June 7, 2006 – Affibody is pleased to announce that clinical imaging data using anti-HER2 Affibody<sup>®</sup> molecules have been presented at the 53<sup>rd</sup> Annual Meeting of the Society of Nuclear Medicine in San Diego, USA (3-7 June 2006).**

The clinical data, showing excellent localization and resolution of breast cancer metastases using an anti-HER2 Affibody<sup>®</sup> imaging agent, is presented by Professor Dr. Richard P. Baum from the Zentralklinik Bad Berka, Germany. High contrast images are presented both from SPECT and PET analyses using Affibody<sup>®</sup> molecules labeled with Indium-111 and Gallium-68, respectively. Due to the excellent selectivity and rapid clearance, high resolution images of metastases in different anatomical sites were obtained only hours following administration of the Affibody<sup>®</sup> imaging agent.

“In the future there could be an important role for the anti-HER2 Affibody<sup>®</sup> imaging agent not only for characterizing the receptor status of patients presenting with recurrent metastatic disease at follow-up investigations, but also in the primary tumor situation,” says Professor Baum. “Molecular imaging of specific tumor receptors fulfils an unmet clinical need and offers strong benefit for the patient in directing appropriate treatment,” he added.

Affibody has developed this imaging agent based on an Affibody<sup>®</sup> molecule that binds specifically to the receptor HER2, which is frequently overexpressed in breast cancer. The positive identification of the HER2 receptor on the surface of the cancer cells gives prognostic information and may guide treatment for the individual patient as a growing number of pharmaceuticals target this receptor, including the monoclonal antibody Herceptin<sup>®</sup> and small molecule kinase inhibitors such as lapatinib. The application of the anti-HER2 Affibody<sup>®</sup> imaging agent may thus become part of a personalized treatment regimen, providing a comprehensive view of HER2 expression in all the patient's metastases. This information is currently unavailable by other means; for example, the currently used PET imaging agent F-18 fluorodeoxyglucose (FDG) is a general marker for increased metabolic activity and does not provide information on specific drug target expression in the cancer lesions.

“These exciting and decisive results show that the Affibody<sup>®</sup> imaging technology has made the critical transition from promising pre-clinical data to proof-of-concept in the clinical setting. The excellent tumor-targeting properties previously seen in non-human imaging studies have now been confirmed in patients with different localization of disease. This lends strong support to our plans to develop and commercialize imaging agents against other well established tumor markers,” says Affibody's Chief Executive Officer Dr. Ulf Boberg.

Continues/



For further information, please contact:

**Affibody AB**

Ulf Boberg, Chief Executive Officer

+46 8 598 838 15

ulf.boberg@affibody.com

Lars Abrahmsén, Chief Scientific Officer

+46 8 598 838 12

lars.abrahmsen@affibody.com

**Citigate Dewe Rogerson**

David Dible, Mark Swallow, Yvonne Alexander

+44 207 638 9571

**About Affibody AB**

Affibody is a life sciences company focusing on oncology. The company has developed a late-stage pipeline of oncology products for molecular imaging, targeted therapy and biotechnology applications.

The key components of Affibody's proprietary technology platform are unique and highly specific affinity ligands: Affibody<sup>®</sup> molecules. These small robust protein molecules are easy to produce and can be designed to bind to any target protein. The Affibody molecules are ideal for molecular imaging. Importantly, the same Affibody<sup>®</sup> molecule can, with a cytotoxic payload, be used for targeted therapeutics. Affibody's vision is to be a leading player in the emerging field of molecular imaging and targeted therapeutics.

The company's lead product for molecular imaging is targeting HER2, a key receptor on e.g. certain breast cancer tumors, and is expected to be commercially launched in 2008. Affibody<sup>®</sup> molecules specific for other oncology targets are in development and will provide a steady stream of new molecular imaging products and subsequently, targeted therapeutic products. Affibody also develops Affibody<sup>®</sup> molecules for various biotechnology and research applications.

Affibody was founded in 1998 by researchers from the Royal Institute of Technology and the Karolinska Institute in Stockholm. Investors in Affibody AB include HealthCap, Schroder Ventures Life Sciences and Investor Growth Capital. Affibody is based in Stockholm, Sweden and has 50 employees. Further information is found on: [www.affibody.com](http://www.affibody.com)

*Statements in this press release that are not strictly historical may be forward-looking and include risks and uncertainties. Therefore, though based on Affibody's current expectations, it should be duly noted that a variety of factors could cause actual results and experiences to differ materially from what is herein expressed. Risks and uncertainties include, but are not limited to, risks associated with the management of growth and international operations (including effects of currency fluctuations), variability of operating results, unforeseen changes in the diagnostic and pharmaceutical markets, market competition, rapid or unexpected changes in technologies, fluctuations in product demand, difficulties to successfully develop, adapt, produce or commercialize products, the ability to identify and develop new products and to differentiate products from those of competitors, as well as various legal hazards.*